Cargando…

Current treatment paradigm and survival outcomes among patients with newly diagnosed multiple myeloma in China: a retrospective multicenter study

OBJECTIVE: Evidence on the prognostic value of autologous stem cell transplantation (ASCT) and minimal residual disease (MRD) dynamics of patients with newly diagnosed multiple myeloma (NDMM) in China is limited. Our objective in the current study was to understand the current care paradigm and outc...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fan, Huishou, Wang, Weida, Zhang, Ya, Wang, Jianxiang, Cheng, Tao, Qiu, Lugui, Wang, Xin, Xia, Zhongjun, An, Gang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Compuscript 2023
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9843447/ https://www.ncbi.nlm.nih.gov/pubmed/36647781 http://dx.doi.org/10.20892/j.issn.2095-3941.2022.0612

Ejemplares similares

PB2005: BORTEZOMIB, LENALIDOMIDE AND DEXAMETHASONE IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS: A REAL-WORLD STUDY OF CHINA
por: Jingyu, X., et al.
Publicado: (2022)

P935: EARLY RELAPSE WITHIN 18 MONTHS (ER18) IS A POWERFUL DYNAMIC PREDICTOR FOR PROGNOSIS AND COULD REVISE STATIC RISK DISTRIBUTION IN PATIENTS WITH NEWLY-DIAGNOSED MULTIPLE MYELOMA
por: Yan, Wenqiang, et al.
Publicado: (2023)

Prognostic value of the Second Revision of the International Staging System (R2-ISS) in a real-world cohort of patients with newly-diagnosed multiple myeloma
por: Yan, Wenqiang, et al.
Publicado: (2023)

Development of a Risk Assessment Model for Early Grade ≥ 3 Infection During the First 3 Months in Patients Newly Diagnosed With Multiple Myeloma Based on a Multicenter, Real-World Analysis in China
por: Shang, Yufeng, et al.
Publicado: (2022)

Prognostic value of the nutritional risk index in patients with newly diagnosed multiple myeloma
por: Zhang, Limei, et al.
Publicado: (2022)

P806: TRACKING THE CLONAL EVOLUTION AND DRUG RESISTANCE PATHWAY OF NEWLY DIAGNOSED MULTIPLE MYELOMA THROUGH SINGLE-CELL RNA SEQUENCING
por: Cui, Jian, et al.
Publicado: (2023)

Inflammatory and Nutritional Scoring System for Predicting Prognosis in Patients with Newly Diagnosed Multiple Myeloma
por: Zhang, Limei, et al.
Publicado: (2023)

Body Mass Index and Overall Survival of Patients with Newly Diagnosed Multiple Myeloma
por: Wang, Bei, et al.
Publicado: (2022)

Impact of residual tumor cells in the stem cell collection on multiple myeloma patients receiving autologous stem cell transplantation
por: Xu, Jingyu, et al.
Publicado: (2023)

Short overview on the current standard of treatment in newly diagnosed multiple myeloma
por: Willenbacher, Ella, et al.
Publicado: (2018)

Prognostic Nomogram for the Overall Survival of Patients with Newly Diagnosed Multiple Myeloma
por: Zhang, Yue, et al.
Publicado: (2019)

Geriatric Assessment to Predict Survival and Risk of Serious Adverse Events in Elderly Newly Diagnosed Multiple Myeloma Patients: A Multicenter Study in China
por: Zhong, Yu-Ping, et al.
Publicado: (2017)

The Association Between Low T3 Syndrome and Survival in Patients With Newly Diagnosed Multiple Myeloma: A Retrospective Study
por: Pan, Qingrong, et al.
Publicado: (2022)

Immunotherapy for multiple myeloma: new chances and hope
por: Xu, Jingyu, et al.
Publicado: (2023)

Ixazomib combined with lenalidomide and dexamethasone chemotherapy for newly diagnosed multiple myeloma in China—Compared with bortezomib/lenalidomide/dexamethasone
por: Huo, Zhongjun, et al.
Publicado: (2022)

Extreme body mass index and survival in newly diagnosed multiple myeloma patients
por: Shah, Urvi A., et al.
Publicado: (2023)

The R2-ISS in a Multicenter Cohort of Chinese Patients With Newly Diagnosed Multiple Myeloma
por: Yang, Peiyu, et al.
Publicado: (2023)

P910: DOES MINIMAL RESIDUAL DISEASE OF STEM CELL COLLECTION HAVE PROGNOSTIC IMPACT ON PATIENTS WITH MULTIPLE MYELOMA?
por: Jingyu, X., et al.
Publicado: (2022)

Oprozomib in patients with newly diagnosed multiple myeloma
por: Hari, Parameswaran, et al.
Publicado: (2019)

Daratumumab in untreated newly diagnosed multiple myeloma
por: Abdallah, Nadine, et al.
Publicado: (2019)

Acquired platelet dysfunction in newly diagnosed myeloma
por: Mortimer, Joshua, et al.
Publicado: (2021)

A Focus on Newly Diagnosed Multiple Myeloma
por: Brigle, Kevin, et al.
Publicado: (2022)

Suppression of the noninvolved pair of the myeloma isotype correlates with poor survival in newly diagnosed and relapsed/refractory patients with myeloma
por: Ludwig, Heinz, et al.
Publicado: (2016)

Daratumumab for the Management of Newly Diagnosed and Relapsed/Refractory Multiple Myeloma: Current and Emerging Treatments
por: Offidani, Massimo, et al.
Publicado: (2021)

Improvement in renal function and its impact on survival in patients with newly diagnosed multiple myeloma
por: Gonsalves, W I, et al.
Publicado: (2015)

30 Years of Improved Survival in Non-Transplant-Eligible Newly Diagnosed Multiple Myeloma
por: Chacon, Aurelia, et al.
Publicado: (2023)

Impact of Treatment Sequencing on Overall Survival in Patients with Transplant-Ineligible Newly Diagnosed Myeloma
por: Fonseca, Rafael, et al.
Publicado: (2023)

Long-term outcomes of different bortezomib-based regimens in Chinese myeloma patients
por: Wang, Hua, et al.
Publicado: (2016)

Clinical Significance of TP53 Abnormalities in Newly Diagnosed Multiple Myeloma
por: Ye, Fang, et al.
Publicado: (2021)

Ixazomib-based frontline therapy in patients with newly diagnosed multiple myeloma in real-life practice showed comparable efficacy and safety profile with those reported in clinical trial: a multi-center study
por: Li, Jing, et al.
Publicado: (2020)

Review of thalidomide in the treatment of newly diagnosed multiple myeloma
por: Cavallo, Federica, et al.
Publicado: (2007)

Laboratory Features of Newly Diagnosed Multiple Myeloma Patients
por: Hussain, Azhar, et al.
Publicado: (2019)

Frontline therapy for newly diagnosed patients with multiple myeloma
por: Jung, Sung-Hoon, et al.
Publicado: (2020)

Recent Advances in the Treatment Of Newly Diagnosed Multiple Myeloma
por: Libby, Edward, et al.
Publicado: (2020)

Immunoparesis in newly diagnosed Multiple Myeloma patients: Effects on overall survival and progression free survival in the Danish population
por: Sørrig, Rasmus, et al.
Publicado: (2017)

Severe renal impairment as an adverse prognostic factor for survival in newly diagnosed multiple myeloma patients
por: Chen, Xuduan, et al.
Publicado: (2020)

High SOX2 expression is associated with poor survival in patients with newly diagnosed multiple myeloma
por: Shan, Xinhe, et al.
Publicado: (2023)

Clinical features and treatment outcome in newly diagnosed Chinese patients with multiple myeloma: results of a multicenter analysis
por: Lu, J, et al.
Publicado: (2014)

Characterisation of immunoparesis in newly diagnosed myeloma and its impact on progression-free and overall survival in both old and recent myeloma trials
por: Heaney, Jennifer L. J., et al.
Publicado: (2018)

Mutations In Thirty Hotspot Genes In Newly Diagnosed Chinese Multiple Myeloma Patients
por: Hu, Ying, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_c119mtgsmjlblg7k016bf1r2f5